Shots:
Boston Scientific has entered into a definitive agreement to acquire Penumbra, expanding its cardiovascular portfolio
As per the deal, Boston Scientific will acquire Penumbra for $374/share, with Penumbra stockholders having the option to receive either $374 in cash or 3.8721 shares of Boston Scientific’s common stock, representing the enterprise value of ~$14.5B; closing expected…
